Eli Lilly’s blockbuster diabetes medication Mounjaro is expected to receive Food and Drug Administration approval as an obesity treatment before the end of the year, which would lead to a surge in demand. Whether there will be enough of the drug is a different question.
Both Lilly and its competitor, Denmark’s Novo Nordisk, which makes Ozempic and its sister drug Wegovy, are struggling to meet skyrocketing demand for their medications. There is no quick fix for that given the complexity of building out manufacturing capacity for the injections. Both companies are investing billions of dollars a year to try to catch up.
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
24World Media does not take any responsibility of the information you see on this page. The content this page contains is from independent third-party content provider. If you have any concerns regarding the content, please free to write us here: contact@24worldmedia.com
Letter: I’m proud to vote for Seth Moulton
Letter: I support Tram T. Nguyen for Congress
Team of the Week – Peabody West (12U)
Gleb Tsipursky, PhD: Lynn employers should give AI-era beginners a first project
Aboyoun: It was never about women
Lynn’s Katie Burt scores Providence College promotion
Peabody playground set to honor Pantapas
Lynn aligns with state on immigration enforcement
Saugus’ Angelo honored for extraordinary service
Swampscott seawall repairs pending state review
Young Lynnfield entrepreneur cleaning up
For Peabody sisters, Walk for Hospice is a family tradition